Analysts Set Tempus AI, Inc. (NASDAQ:TEM) Target Price at $61.18

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $61.18.

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. TD Cowen reiterated a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Needham & Company LLC increased their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Morgan Stanley lifted their target price on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Finally, Loop Capital lowered their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th.

Tempus AI Trading Down 8.3 %

Tempus AI stock opened at $45.74 on Friday. Tempus AI has a 12 month low of $22.89 and a 12 month high of $91.45. The stock has a fifty day simple moving average of $55.65 and a two-hundred day simple moving average of $51.50. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the sale, the chief operating officer now owns 982,442 shares in the company, valued at approximately $38,914,527.62. This represents a 2.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,561,814 shares of company stock valued at $315,485,164.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kovitz Investment Group Partners LLC purchased a new stake in Tempus AI during the 3rd quarter valued at approximately $1,367,000. China Universal Asset Management Co. Ltd. bought a new stake in Tempus AI in the 4th quarter valued at $1,091,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Tempus AI in the 4th quarter worth $178,000. Captrust Financial Advisors bought a new position in shares of Tempus AI during the 3rd quarter valued at about $2,726,000. Finally, abrdn plc bought a new position in shares of Tempus AI during the 4th quarter valued at about $2,784,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.